Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?
Tough Conditions Will Persist In 2023
Nov 16 2022
•
By
Andrew McConaghie
Around 85% of companies which IPO'd in 2020 and 2021 are currently below their initial market values, reflecting a harsher environment. • Source: Shutterstock
More from Business
More from Scrip